News & Blog
MD Anderson and Cynvenio Biosystems, Inc. announce the beginning of the final clinical validation phase of Cynvenio LungLB(TM).
Cynvenio announced the launch of its new HER2 Expression test that allows doctors to perform real-time monitoring and analysis of HER2 levels in their patients without using tissue biopsy.
New Study will use LiquidBiopsy® ClearID® testing and NK Score™ natural killer cell activity testing to monitor breast cancer patients following neoadjuvant chemotherapy.
Cynvenio launches a new, high sensitivity PD-L1 blood test that provides real time information to support treatment strategy and monitoring for Lung Cancer patients.
LiquidBiopsy automated rare cell isolation platform enables quick-turnaround sample-to-sequence workflows at Gangnam Severance Hospital, supporting cancer research and genomic testing of cancer patients.
The 64-seater plane skips and hops on the high winds over the Rockies. Then suddenly all is calm as we glide down into the valley that shields Missoula, Montana. I’m going to Cancer Camp.
As it is, I’ve seen the future, and we can stop fighting. Health food nuts and science geeks—all our work is relevant... It’s integrative therapy. It’s faith and fact, in one unbroken circle. It’s the ground where one day we will be healed.
Global cancer rates continue to rise due to many different factors, so besides research, clinical trials and advances in modern medicine, the best we can personally do to combat this is make positive lifestyle changes, be engaged in the political process to not only look out for our own healthcare needs but for those of our fellow citizens...
Give cancer a face, and you’ve already cut it down a peg. Give it a face, and you can tell that face to get out of your house. I’m not saying we shouldn’t be afraid. That would be insane. But we shouldn’t despair, either. Cancer is not that strong. I can’t outrun a judgment. But against an illness, I’ve always got a chance.